{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:43:43Z","timestamp":1794577423803,"version":"4.9.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T00:00:00Z","timestamp":1583280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T00:00:00Z","timestamp":1583280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-020-0286-5","type":"journal-article","created":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T12:03:25Z","timestamp":1583323405000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Veno-occlusive disease\/sinusoidal obstruction syndrome in patients with prior gemtuzumab ozogamicin: literature analysis of survival after defibrotide treatment"],"prefix":"10.1038","volume":"10","author":[{"given":"Paul G.","family":"Richardson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selim","family":"Corbacioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,4]]},"reference":[{"key":"286_CR1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","volume":"16","author":"JA Coppell","year":"2010","unstructured":"Coppell, J. A. et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol. Blood Marrow Transplant. 16, 157\u2013168 (2010).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"286_CR2","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.bbmt.2015.09.024","volume":"22","author":"JH Dalle","year":"2016","unstructured":"Dalle, J. H. & Giralt, S. A. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment. Biol. Blood Marrow Transplant. 22, 400\u2013409 (2016).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"286_CR3","doi-asserted-by":"publisher","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","volume":"4","author":"HM Kantarjian","year":"2017","unstructured":"Kantarjian, H. M. et al. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 4, e387\u2013e398 (2017).","journal-title":"Lancet Haematol."},{"key":"286_CR4","unstructured":"MylotargTM (gemtuzumab ozogamicin) [packet insert] (Wyeth Pharmaceuticals Inc., Philadelphia, 2018)."},{"key":"286_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.leukres.2016.03.004","volume":"44","author":"JS Magwood-Golston","year":"2016","unstructured":"Magwood-Golston, J. S., Kessler, S. & Bennett, C. L. Evaluation of gemtuzumab ozogamycin associated sinusoidal obstructive syndrome: findings from an academic pharmacovigilance program review and a pharmaceutical sponsored registry. Leuk. Res. 44, 61\u201364 (2016).","journal-title":"Leuk. Res."},{"key":"286_CR6","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1200\/JCO.2015.64.0060","volume":"34","author":"S Amadori","year":"2016","unstructured":"Amadori, S. et al. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial. J. Clin. Oncol. 34, 972\u2013979 (2016).","journal-title":"J. Clin. Oncol."},{"key":"286_CR7","unstructured":"MylotargTM [summary of roduct characteristics]. (Pfizer Ireland Pharmaceuticals, Ireland, 2018)."},{"key":"286_CR8","unstructured":"Defitelio (defibrotide sodium) injection [packet insert] (Jazz Pharmaceuticals Inc., 2016)."},{"key":"286_CR9","volume-title":"Summary of Product Characteristics.","author":"Defitelio.","year":"2013","unstructured":"Defitelio. Summary of Product Characteristics. (Gentium SpA, Villa Guardia, Italy, 2013)."},{"key":"286_CR10","unstructured":"Defitelio Product Monograph (Jazz Pharmaceuticals Ireland, Limited, Dublin, Ireland, 2017)."},{"key":"286_CR11","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/bjh.12558","volume":"163","author":"FL Dignan","year":"2013","unstructured":"Dignan, F. L. et al. BCSH\/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br. J. Haematol. 163, 444\u2013457 (2013).","journal-title":"Br. J. Haematol."},{"key":"286_CR12","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1182\/blood-2017-01-762419","volume":"129","author":"CD Godwin","year":"2017","unstructured":"Godwin, C. D., McDonald, G. B. & Walter, R. B. Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia. Blood 129, 2330\u20132332 (2017).","journal-title":"Blood"},{"key":"286_CR13","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jceh.2014.10.002","volume":"4","author":"CQ Fan","year":"2014","unstructured":"Fan, C. Q. & Crawford, J. M. Sinusoidal obstruction syndrome (hepatic veno-occlusive disease). J. Clin. Exp. Hepatol. 4, 332\u2013346 (2014).","journal-title":"J. Clin. Exp. Hepatol."},{"key":"286_CR14","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/bmt.2016.302","volume":"52","author":"G Battipaglia","year":"2017","unstructured":"Battipaglia, G. et al. Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant. 52, 592\u2013599 (2017).","journal-title":"Bone Marrow Transplant."},{"key":"286_CR15","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.bbmt.2010.02.009","volume":"16","author":"PG Richardson","year":"2010","unstructured":"Richardson, P. G. et al. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol. Blood Marrow Transplant. 16, 1005\u20131017 (2010).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"286_CR16","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/j.1365-2141.2009.08011.x","volume":"148","author":"CM Zwaan","year":"2010","unstructured":"Zwaan, C. M. et al. Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. Br. J. Haematol. 148, 768\u2013776 (2010).","journal-title":"Br. J. Haematol."},{"key":"286_CR17","doi-asserted-by":"publisher","first-page":"5585","DOI":"10.1158\/1078-0432.CCR-08-0894","volume":"14","author":"M Bornhauser","year":"2008","unstructured":"Bornhauser, M. et al. Gemtuzumab ozogamicin as part of reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in patients with relapsed acute myeloid leukemia. Clin. Cancer Res. 14, 5585\u20135593 (2008).","journal-title":"Clin. Cancer Res."},{"key":"286_CR18","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/j.1365-2710.2006.00742.x","volume":"31","author":"D Lannoy","year":"2006","unstructured":"Lannoy, D. et al. Gemtuzumab ozogamicin-induced sinusoidal obstructive syndrome treated with defibrotide: a case report. J. Clin. Pharm. Ther. 31, 389\u2013392 (2006).","journal-title":"J. Clin. Pharm. Ther."},{"key":"286_CR19","first-page":"269","volume":"27","author":"D Reinhardt","year":"2004","unstructured":"Reinhardt, D. et al. Gemtuzumab ozogamicin (Mylotarg) in children with refractory or relapsed acute myeloid leukemia. Onkologie 27, 269\u2013272 (2004).","journal-title":"Onkologie"},{"key":"286_CR20","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1182\/blood-2003-10-3612","volume":"103","author":"B Versluys","year":"2004","unstructured":"Versluys, B. et al. Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure. Blood 103, 1968 (2004).","journal-title":"Blood"},{"key":"286_CR21","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1046\/j.1365-2141.2003.04667.x","volume":"123","author":"A Saviola","year":"2003","unstructured":"Saviola, A. et al. Late occurrence of hepatic veno-occlusive disease following gemtuzumab ozogamicin: successful treatment with defibrotide. Br. J. Haematol. 123, 752\u2013753 (2003).","journal-title":"Br. J. Haematol."},{"key":"286_CR22","doi-asserted-by":"publisher","first-page":"4310","DOI":"10.1182\/blood.V126.23.4310.4310","volume":"126","author":"S Corbacioglu","year":"2015","unstructured":"Corbacioglu, S. et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in pediatric hematopoietic stem cell transplantation: subanalysis data from an open-label, phase III, randomized trial. Blood 126, 4310 (2015).","journal-title":"Blood"},{"key":"286_CR23","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1182\/blood-2015-10-676924","volume":"127","author":"PG Richardson","year":"2016","unstructured":"Richardson, P. G. et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood 127, 1656\u20131665 (2016).","journal-title":"Blood"},{"key":"286_CR24","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian, H. M. et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N. Engl. J. Med. 375, 740\u2013753 (2016).","journal-title":"N. Engl. J. Med."},{"key":"286_CR25","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1182\/bloodadvances.2016001925","volume":"1","author":"DJ DeAngelo","year":"2017","unstructured":"DeAngelo, D. J. et al. Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1\/2 study. Blood Adv. 1, 1167\u20131180 (2017).","journal-title":"Blood Adv."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0286-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0286-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0286-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T14:26:11Z","timestamp":1670250371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0286-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,4]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["286"],"URL":"https:\/\/doi.org\/10.1038\/s41408-020-0286-5","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,4]]},"assertion":[{"value":"11 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.G.R. has served on advisory committees and received research funding from Jazz Pharmaceuticals. S.C. has served as a consultant to and received honoraria from Gentium\/Jazz Pharmaceuticals.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"29"}}